Answers are grounded in this paper and cite their sources.
Microencapsulation of risperidone in a PLGA matrix is considered as a suitable drug delivery system to overcome the limitations of oral risperidone administration, such as fluctuations in plasma drug levels and low patient compliance. There are several crucial process parameters in the design of PLGA-based microsphere formulations, including emulsification speed, PLGA concentration, and PVA concentration. In addition, the drying method also contributes to the encapsulation efficiency of the microspheres. Therefore, this study aims to combine the optimization of process parameters in PLGA microspheres formulation with variations in drying methods to obtain PLGA microspheres with the most optimal properties and encapsulation efficiency for further use in risperidone-loaded microspheres as a long-acting injectable formulation. The optimal formula was achieved at an emulsification speed of 1500 rpm, a PLGA concentration of 250 mg/ml, and a PVA concentration of 0.5%, which produced microspheres with spherical morphology with controlled porosity, appropriate particle size (2.25 ± 0.17 µm), appropriate polydispersity (PDI 0.81 ± 0.04), and a thermal profile suitable for pharmaceutical applications. Desiccator drying was selected as the most optimal drying method for risperidone-loaded PLGA microspheres because it produced the highest drug loading and encapsulation efficiency values, 26.85% and 70.48% respectively. This approach aims to make a significant contribution to the development of PLGA-based microencapsulation systems for stable and sustained therapy.
No takes yet. Share an insight, caveat, or question.
Nirwana et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: